This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stevenson, J. P. Articles by O'Dwyer, P. J. Search for Related Content PubMed PubMed Citation Articles by Stevenson, J. P. Articles by O'Dwyer, P. J. Social Bookmarking                            What's this?

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

From the Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, PA; and ISIS Pharmaceuticals, Inc, Carlsbad, CA.

Address reprint requests to James P. Stevenson, MD, University of Pennsylvania, Presbyterian Medical Center, Medical Arts Building, Suite 103, 51 North 39th St, Philadelphia, PA 19104.

PURPOSE: Raf-1 is a protein kinase that plays a broad role in oncogenic signaling and acts as a downstream effector of Ras in the mitogen-activated protein kinase pathway. The present study was designed to determine the maximum-tolerated dose (MTD), toxicity profile, pharmacokinetics, and antitumor activity of the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A; ISIS Pharmaceuticals Inc, Carlsbad, CA). The effect of ISIS 5132 on c-raf-1 gene expression in peripheral-blood mononuclear cells (PBMCs) of treated patients was studied using a reverse transcriptase polymerase chain reaction assay.

PATIENTS AND METHODS: Patients with refractory malignancies received ISIS 5132 as a 2-hour intravenous infusion three times weekly for 3 consecutive weeks. Pharmacokinetic sampling was performed during the first cycle in all patients; PBMCs for c-raf-1 mRNA analysis were collected at baseline and on days 3, 5, 8, and 15 of cycle 1 and on day 1 of each cycle thereafter.

RESULTS: Thirty-one patients received ISIS 5132 at one of nine dose levels ranging from 0.5 mg/kg to 6.0 mg/kg. Clinical toxicities included fever and fatigue, but these were not dose limiting. A clinically defined MTD was not reached. The harmonic mean half-life of ISIS 5132 was 59.8 minutes (range, 35.5 to 107.3 minutes). The area under the concentration-time curve increased linearly with dose, and mean plasma clearance was 1.86 mL/kg/min (range, 1.21 to 2.41 mL/kg/min). Two patients experienced prolonged stable disease lasting more than 7 months, which was associated with persistent reduction in c-raf-1 expression in PBMCs. Significant decreases in c-raf-1 expression were identified at time points after the baseline value (P < .05) at doses 2.5 mg/kg.

CONCLUSION: ISIS 5132 is well tolerated at doses up to 6.0 mg/kg when administered as a thrice weekly 2-hour infusion for 3 consecutive weeks. The pharmacokinetic behavior of the drug is reproducible, and suppression of target gene expression is observed in circulating PBMCs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Beeram, A. Patnaik, and E. K. Rowinsky Raf: A Strategic Target for Therapeutic Development Against Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790. [Abstract] [Full Text] [PDF]

				W. R. Parulekar and E. A. Eisenhauer Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997. [Abstract] [Full Text] [PDF]

				P. Mullen, F. McPhillips, K. MacLeod, B. Monia, J. F. Smyth, and S. P. Langdon Antisense Oligonucleotide Targeting of Raf-1: Importance of Raf-1 mRNA Expression Levels and Raf-1-Dependent Signaling in Determining Growth Response in Ovarian Cancer Clin. Cancer Res., March 15, 2004; 10(6): 2100 - 2108. [Abstract] [Full Text] [PDF]

				R. S. Geary, R. Z. Yu, T. Watanabe, S. P. Henry, G. E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A. A. Levin PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-{alpha} PHOSPHOROTHIOATE 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES Drug Metab. Dispos., November 1, 2003; 31(11): 1419 - 1428. [Abstract] [Full Text] [PDF]

				C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma J Natl Cancer Inst, September 17, 2003; 95(18): 1394 - 1403. [Abstract] [Full Text] [PDF]

				M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman The Hsp90 chaperone complex as a novel target for cancer therapy Ann. Onc., August 1, 2003; 14(8): 1169 - 1176. [Abstract] [Full Text] [PDF]

				M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF]

				K. Fluiter, A. L. M. A. ten Asbroek, M. B. de Wissel, M. E. Jakobs, M. Wissenbach, H. Olsson, O. Olsen, H. Oerum, and F. Baas In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides Nucleic Acids Res., February 1, 2003; 31(3): 953 - 962. [Abstract] [Full Text] [PDF]

				B. Boettner and L. Van Aelst The RASputin effect Genes & Dev., August 15, 2002; 16(16): 2033 - 2038. [Full Text] [PDF]

				N. M. Hamad, J. H. Elconin, A. E. Karnoub, W. Bai, J. N. Rich, R. T. Abraham, C. J. Der, and C. M. Counter Distinct requirements for Ras oncogenesis in human versus mouse cells Genes & Dev., August 15, 2002; 16(16): 2045 - 2057. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, L. Reyno, P. M. Venner, S. D. Ernst, M. Moore, R. S. Geary, K. Chi, S. Hall, W. Walsh, A. Dorr, et al. A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2530 - 2535. [Abstract] [Full Text] [PDF]

				M. C. Cripps, A. T. Figueredo, A. M. Oza, M. J. Taylor, A. L. Fields, J. T. Holmlund, L. W. McIntosh, R. S. Geary, and E. A. Eisenhauer Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study Clin. Cancer Res., July 1, 2002; 8(7): 2188 - 2192. [Abstract] [Full Text] [PDF]

				G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part I J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894. [Abstract] [Full Text] [PDF]

				S. M. Luger, S. G. O'Brien, J. Ratajczak, M. Z. Ratajczak, R. Mick, E. A. Stadtmauer, P. C. Nowell, J. M. Goldman, and A. M. Gewirtz Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study Blood, February 15, 2002; 99(4): 1150 - 1158. [Abstract] [Full Text] [PDF]

				C. M. Rudin, J. Holmlund, G. F. Fleming, S. Mani, W. M. Stadler, P. Schumm, B. P. Monia, J. F. Johnston, R. Geary, R. Z. Yu, et al. Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1214 - 1220. [Abstract] [Full Text]

				R. Z. Yu, H. Zhang, R. S. Geary, M. Graham, L. Masarjian, K. Lemonidis, R. Crooke, N. M. Dean, and A. A. Levin Pharmacokinetics and Pharmacodynamics of an Antisense Phosphorothioate Oligonucleotide Targeting Fas mRNA in Mice J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 388 - 395. [Abstract] [Full Text]

				R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 890 - 897. [Abstract] [Full Text]

				H J N Andreyev, P J Ross, D Cunningham, and P A Clarke Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma Gut, February 1, 2001; 48(2): 230 - 237. [Abstract] [Full Text] [PDF]

				B. H. Dvorchik and J. K. Marquis Disposition and Toxicity of a Mixed Backbone Antisense Oligonucleotide, Targeted against Human Cytomegalovirus, after Intravitreal Injection of Escalating Single Doses in the Rabbit Drug Metab. Dispos., October 1, 2000; 28(10): 1255 - 1261. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, Sabino De Placido, A. R. Bianco, J. Mendelsohn, and G. Tortora Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3739 - 3747. [Abstract] [Full Text]

				F. R. Khuri and J. M. Kurie Antisense Approaches Enter the Clinic Clin. Cancer Res., May 1, 2000; 6(5): 1607 - 1610. [Full Text]

				C. C. Cunningham, J. T. Holmlund, J. H. Schiller, R. S. Geary, T. J. Kwoh, A. Dorr, and J. Nemunaitis A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1626 - 1631. [Abstract] [Full Text]

				H. Roh, J. Pippin, and J. A. Drebin Down-Regulation of HER2/neu Expression Induces Apoptosis in Human Cancer Cells That Overexpress HER2/neu Cancer Res., February 1, 2000; 60(3): 560 - 565. [Abstract] [Full Text]

				P. J. O'Dwyer, J. P. Stevenson, M. Gallagher, A. Cassella, I. Vasilevskaya, B. P. Monia, J. Holmlund, F. A. Dorr, and K.-S. Yao c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A) Clin. Cancer Res., December 1, 1999; 5(12): 3977 - 3982. [Abstract] [Full Text] [PDF]